---
schema_version: "secwatch.filing_event.v1"
accession: "0001962918-24-000030"
form_type: "8-K"
ticker: null
cik: "0001962918"
company_name: "ACELYRIN, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:43:19.224259+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ACELYRIN reports FY 2023 net loss of $381.6M; cash $721.3M; pipeline progress with izokibep and lonigutamab

## Summary
- Net loss $381.6M in 2023 vs $64.8M in 2022; R&D expenses $355.9M including $123.1M IPR&D from ValenzaBio acquisition.
- Cash, equivalents and marketable securities $721.3M expected to fund operations into 2026 through late-stage registrational studies.
- Positive Phase 1/2 data for lonigutamab (subcutaneous anti-IGF-1R) in thyroid eye disease with rapid proptosis improvements at 3 weeks.
- Phase 2b/3 trial of izokibep met primary endpoint ACR50 at 16 weeks with high statistical significance in psoriatic arthritis; HS Phase 3 topline data expected H2 2024.
- Appointed Agnes Lee as SVP IR and Corporate Communications; Lynn Tetrault joined Board in December 2023.

## SEC filing metadata
- accession: 0001962918-24-000030
- form_type: 8-K
- cik: 0001962918
- company_name: ACELYRIN, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962918/000196291824000030/0001962918-24-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962918/000196291824000030/slrn-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001962918-24-000030
- JSON: https://secwatch.observer/filing/0001962918-24-000030.json
- Plain text: https://secwatch.observer/filing/0001962918-24-000030.txt

## Key facts
- Earnings Releases
  ACELYRIN, Inc. reported the full year ended December 31, 2023 results: net income Net loss for the full year ended December 31, 2023 was $381.6 million, compared to $64.8 million for 2022..
  - Period: the full year ended December 31, 2023
  - Net income: Net loss for the full year ended December 31, 2023 was $381.6 million, compared to $64.8 million for 2022.
  - Result: reported results
  source text: On March 28, 2024, ACELYRIN, INC. (the " Company ") issued a press release announcing its financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1962918/000196291824000030/0001962918-24-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.